摘要
目的 探讨不同剂量利伐沙班治疗老年心力衰竭(HF)合并房颤(AF)患者的临床效果及安全性。方法 选取2020年1月至2022年1月我院收治的80例老年HF合并AF患者,随机均分为两组。在常规治疗基础上,对照组给予20 mg/d利伐沙班治疗,研究组给予10 mg/d利伐沙班治疗。比较两组的凝血功能、心功能以及不良事件。结果 治疗1个月后,两组的凝血功能指标(D-D、 PT)和心功能指标(NT-proBNP、 LVEF)均较治疗前显著改善(P <0.05),但组间比较差异无统计学意义(P>0.05)。随访6个月,研究组的不良事件发生率为7.50%,显著低于对照组的25.00%(P <0.05)。结论 10 mg/d与20 mg/d剂量利伐沙班治疗老年HF合并AF患者的效果相当,均可有效改善凝血功能和心功能,但10 mg/d剂量的不良事件发生率较低。
Objective To compare the clinical effects and safety of different doses of rivaroxaban in the treatment of elderly patients with heart failure(HF) complicated with atrial fibrillation(AF).Methods A total of 80 elderly patients with HF complicated with AF admitted to our hospital from January 2020 to January 2022 were selected and randomly and equally divided into two groups.On the basis of routine treatment,the control group was treated with 20 mg/d rivaroxaban,and the study group was treated with 10 mg/d rivaroxaban.The coagulation function,cardiac function and adverse events were compared between the two groups.Results After 1 month of treatment,the coagulation function indicators(D-D,PT) and cardiac function indicators(NT-proBNP,LVEF) of the two groups were significantly improved compared with those before treatment(P <0.05),while no statistical difference was found between the two groups(P >0.05).Within 6months of follow-up,the incidence of adverse events in the study group was 7.50%,significantly lower than 25.00% in the control group(P<0.05).Conclusions 10 mg/d dose of rivaroxaban and 20 mg/d dose of rivaroxaban in the treatment of elderly patients with HF complicated with AF have equivalent effect,which can effectively improve coagulation function and cardiac function,but the incidence of adverse events of 10 mg/d dose is lower.
作者
蒋艳利
姬小慧
JIANG Yanli;JI Xiaohui(Department of Emergency Internal Medicine,Anyang Second People's Hospital,Anyang 455000,China)
出处
《临床医学工程》
2024年第2期189-190,共2页
Clinical Medicine & Engineering
关键词
不同剂量
利伐沙班
心力衰竭
房颤
凝血功能
心功能
不良事件
Different doses
Rivaroxaban
Heart failure
Atrial fibrillation
Coagulation function
Cardiac function
Adverse event
